Percutaneous left atrial appendage (LAA) suture ligation using the LARIAT (SentreHEART Inc, Redwood, CA) device in patients with atrial fibrillation (AF) for the prevention of thromboembolic events was introduced in 2009. The Polish recommendations regarding LAA closure published in 2018 also presented this uncommonly used surgical technology to occlude the LAA in high-risk AF patients \[[@cit0001]\]. I read with keen interest the article by Litwinowicz *et al.* in the latest issue of *Advances in Intervential Cardiology*, in which the authors reported clinical outcomes in 139 patients following the use of the LARIAT device to close the LAA from December 2009 to December 2010 \[[@cit0002]\]. A key finding of the study is no difference in rates of thromboembolic and bleeding events as well as mortality between anticoagulated and non-anticoagulated AF patients during up to 60 months of follow-up. The former group involved 75 of the 139 patients, including 40% of anticoagulated subjects on a vitamin K antagonist (VKA) and 18% on non-VKA oral antagonists (NOAC) at the end of follow-up \[[@cit0002]\]. Apart from a rather surprisingly large proportion of AF patients in whom the procedure was performed with continued anticoagulation, which had been previously assessed as contraindicated or ineffective, it would be interesting to provide data on the indication for LAA closure and quality of anticoagulation with VKA. Three thromboembolic arterial events were observed on VKA, which suggests poor quality of anticoagulant therapy. This speculation could be supported by the fact that a single major bleeding event was observed on VKA during follow-up, which is a rather uncommon finding in patients on VKA. The current study could also be considered as an additional indirect suggestion to widely use NOAC in AF patients as recommended by most experts especially in AF patients at high thromboembolic and bleeding risk, similar to the present patient population \[[@cit0003]\]. From a practical point of view, it would be of interest to provide more data on the subsequent therapeutic strategy after the adverse events reported here. Were the patients with adverse events switched to other treatment strategies? Were patients after severe bleeding off anticoagulation? It is unclear whether the clinical outcomes could be affected by patients' age as the most relevant risk factor for both thromboembolism and bleeding in AF \[[@cit0003]\]. In a previous study, Litwinowicz *et al.* \[[@cit0004]\] found that during long-term follow-up thromboembolic risk after LAA occlusion was not related to this potent stroke risk factor. Did the authors look at a composite of efficacy and safety endpoints to determine whether age affects the study results?

Taken together, the study by Litwinowicz *et al.* \[[@cit0002]\] presented unique follow-up data on AF patients following LAA occlusion with the LARIAT device, which underscore the need for appropriate decision-making to balance the risk and benefits from the procedure in high-risk patients, followed by either long-term anticoagulation, preferably with NOACs, or not.
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